DLL3 CAR-T Therapy Targeting Brain Tumors

Clinical trial NCT07180927 · RECRUITING

Trial details

NCT number: NCT07180927
Sponsor: Shenzhen Geno-Immune Medical Institute
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Glioblastoma of Cerebellum

Start date: 2025-09-10
Primary completion: 2028-12-31
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.